Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023246458> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W2023246458 endingPage "S66" @default.
- W2023246458 startingPage "S66" @default.
- W2023246458 abstract "Benign prostatic hyperplasia (BPH) is one of the most common medical conditions in older men in the United States. BPH is often associated with a reduction in quality of life and may progress to acute urinary retention (AUR), the inability to pass any urine. Recently, a 4-year placebo-controlled clinical trial known as the Proscar® Long-Term Efficacy and Safety Study (PLESS) demonstrated that finasteride use reduces the risk of developing AUR by 57% and the need for BPH-related surgery by 55%. The economic implications of these findings were investigated using a model-based decision-analytic approach to compare finasteride with both watchful waiting and α-blocker therapy. The modeling used the longest-term published controlled data concerning α-blockers, which were for the a-blocker terazosin. The base case considered a 64-year-old man (the mean age of a PLESS patient) with prostatic enlargement on digital rectal examination and moderate-to-severe symptoms of BPH. The model suggested savings in surgical and AUR costs with finasteride versus watchful waiting, with an estimated 25% of total finasteride costs recouped in savings on surgical events avoided in the first year. Over 2 years, the expected cost per patient starting finasteride therapy was $2304, whereas the expected cost per patient starting terazosin was $2334. Analyses also explored the variation in economic results by baseline levels of prostate-specific antigen (PSA), a proxy for prostate volume. For patients with PSA levels ≥1.4 ng/mL, expected 2-year costs with finasteride and terazosin were $2342 and $2479, respectively. For patients with PSA levels ≥3.3 ng/mL, expected 2-year costs with finasteride were $373 less than with terazosin ($2347 vs $2720). Results were robust over a range of model assumptions and cost estimates. The analyses illustrate that all medical interventions, including watchful waiting, have associated costs. Finasteride shows cost offsets compared with watchful waiting and cost savings compared with terazosin over 2 years. Finasteride appears to be more economical in men with higher PSA levels." @default.
- W2023246458 created "2016-06-24" @default.
- W2023246458 creator A5074765404 @default.
- W2023246458 creator A5077547822 @default.
- W2023246458 date "1998-06-01" @default.
- W2023246458 modified "2023-09-26" @default.
- W2023246458 title "Analyzing a continuous efficacy response in a long-term trial with high dropout rate" @default.
- W2023246458 doi "https://doi.org/10.1016/s0197-2456(98)80168-2" @default.
- W2023246458 hasPublicationYear "1998" @default.
- W2023246458 type Work @default.
- W2023246458 sameAs 2023246458 @default.
- W2023246458 citedByCount "0" @default.
- W2023246458 crossrefType "journal-article" @default.
- W2023246458 hasAuthorship W2023246458A5074765404 @default.
- W2023246458 hasAuthorship W2023246458A5077547822 @default.
- W2023246458 hasConcept C121608353 @default.
- W2023246458 hasConcept C126322002 @default.
- W2023246458 hasConcept C126894567 @default.
- W2023246458 hasConcept C142724271 @default.
- W2023246458 hasConcept C204787440 @default.
- W2023246458 hasConcept C27081682 @default.
- W2023246458 hasConcept C2775874879 @default.
- W2023246458 hasConcept C2776141087 @default.
- W2023246458 hasConcept C2776235491 @default.
- W2023246458 hasConcept C2776679619 @default.
- W2023246458 hasConcept C2777562237 @default.
- W2023246458 hasConcept C2780192828 @default.
- W2023246458 hasConcept C2780542891 @default.
- W2023246458 hasConcept C29456083 @default.
- W2023246458 hasConcept C71924100 @default.
- W2023246458 hasConceptScore W2023246458C121608353 @default.
- W2023246458 hasConceptScore W2023246458C126322002 @default.
- W2023246458 hasConceptScore W2023246458C126894567 @default.
- W2023246458 hasConceptScore W2023246458C142724271 @default.
- W2023246458 hasConceptScore W2023246458C204787440 @default.
- W2023246458 hasConceptScore W2023246458C27081682 @default.
- W2023246458 hasConceptScore W2023246458C2775874879 @default.
- W2023246458 hasConceptScore W2023246458C2776141087 @default.
- W2023246458 hasConceptScore W2023246458C2776235491 @default.
- W2023246458 hasConceptScore W2023246458C2776679619 @default.
- W2023246458 hasConceptScore W2023246458C2777562237 @default.
- W2023246458 hasConceptScore W2023246458C2780192828 @default.
- W2023246458 hasConceptScore W2023246458C2780542891 @default.
- W2023246458 hasConceptScore W2023246458C29456083 @default.
- W2023246458 hasConceptScore W2023246458C71924100 @default.
- W2023246458 hasIssue "3" @default.
- W2023246458 hasLocation W20232464581 @default.
- W2023246458 hasOpenAccess W2023246458 @default.
- W2023246458 hasPrimaryLocation W20232464581 @default.
- W2023246458 hasRelatedWork W110432453 @default.
- W2023246458 hasRelatedWork W1551831141 @default.
- W2023246458 hasRelatedWork W2067609693 @default.
- W2023246458 hasRelatedWork W2366055913 @default.
- W2023246458 hasRelatedWork W2389954374 @default.
- W2023246458 hasRelatedWork W2397598598 @default.
- W2023246458 hasRelatedWork W2413929055 @default.
- W2023246458 hasRelatedWork W3133788711 @default.
- W2023246458 hasRelatedWork W4232662359 @default.
- W2023246458 hasRelatedWork W4237663250 @default.
- W2023246458 hasVolume "19" @default.
- W2023246458 isParatext "false" @default.
- W2023246458 isRetracted "false" @default.
- W2023246458 magId "2023246458" @default.
- W2023246458 workType "article" @default.